BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication, help guide management, and facilitate research. OBJECTIVE: To develop a multidimensional prognostic staging system for IPF by using commonly measured clinical and physiologic variables. DESIGN: A clinical prediction model was developed and validated by using retrospective data from 3 large, geographically distinct cohorts. SETTING: Interstitial lung disease referral centers in California, Minnesota, and Italy. PATIENTS: 228 patients with IPF at the University of California, San Francisco (derivation cohort), and 330 patients at the Mayo Clinic and Morgagni-Pierantoni Hospital (validation cohort). MEASUREMENTS: The primary outcome was mortality, treating transplantation as a competing risk. Model discrimination was assessed by the c-index, and calibration was assessed by comparing predicted and observed cumulative mortality at 1, 2, and 3 years. RESULTS: Four variables were included in the final model: gender (G), age (A), and 2 lung physiology variables (P) (FVC and Dlco). A model using continuous predictors (GAP calculator) and a simple point-scoring system (GAP index) performed similarly in derivation (c-index of 70.8 and 69.3, respectively) and validation (c-index of 69.1 and 68.7, respectively). Three stages (stages I, II, and III) were identified based on the GAP index with 1-year mortality of 6%, 16%, and 39%, respectively. The GAP models performed similarly in pooled follow-up visits (c-index ≥71.9). LIMITATION: Patients were drawn from academic centers and analyzed retrospectively. CONCLUSION: The GAP models use commonly measured clinical and physiologic variables to predict mortality in patients with IPF.
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication, help guide management, and facilitate research. OBJECTIVE: To develop a multidimensional prognostic staging system for IPF by using commonly measured clinical and physiologic variables. DESIGN: A clinical prediction model was developed and validated by using retrospective data from 3 large, geographically distinct cohorts. SETTING:Interstitial lung disease referral centers in California, Minnesota, and Italy. PATIENTS: 228 patients with IPF at the University of California, San Francisco (derivation cohort), and 330 patients at the Mayo Clinic and Morgagni-Pierantoni Hospital (validation cohort). MEASUREMENTS: The primary outcome was mortality, treating transplantation as a competing risk. Model discrimination was assessed by the c-index, and calibration was assessed by comparing predicted and observed cumulative mortality at 1, 2, and 3 years. RESULTS: Four variables were included in the final model: gender (G), age (A), and 2 lung physiology variables (P) (FVC and Dlco). A model using continuous predictors (GAP calculator) and a simple point-scoring system (GAP index) performed similarly in derivation (c-index of 70.8 and 69.3, respectively) and validation (c-index of 69.1 and 68.7, respectively). Three stages (stages I, II, and III) were identified based on the GAP index with 1-year mortality of 6%, 16%, and 39%, respectively. The GAP models performed similarly in pooled follow-up visits (c-index ≥71.9). LIMITATION: Patients were drawn from academic centers and analyzed retrospectively. CONCLUSION: The GAP models use commonly measured clinical and physiologic variables to predict mortality in patients with IPF.
Authors: Rebeccah M Brusca; Iago Pinal-Fernandez; Kevin Psoter; Julie J Paik; Jemima Albayda; Christopher Mecoli; Eleni Tiniakou; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff; Cheilonda Johnson Journal: Respir Med Date: 2019-02-21 Impact factor: 3.415
Authors: Antje Prasse; Harald Binder; Jonas C Schupp; Gian Kayser; Elena Bargagli; Benedikt Jaeger; Moritz Hess; Susanne Rittinghausen; Louis Vuga; Heather Lynn; Shelia Violette; Birgit Jung; Karsten Quast; Bart Vanaudenaerde; Yan Xu; Jens M Hohlfeld; Norbert Krug; Jose D Herazo-Maya; Paola Rottoli; Wim A Wuyts; Naftali Kaminski Journal: Am J Respir Crit Care Med Date: 2019-03-01 Impact factor: 21.405
Authors: Jorge A Zamora-Legoff; Megan L Krause; Cynthia S Crowson; Jay H Ryu; Eric L Matteson Journal: Rheumatology (Oxford) Date: 2017-03-01 Impact factor: 7.580